Seat­tle's Uni­ver­sal Cells brings Astel­las in­to its fold of off-the-shelf cell ther­a­py part­ners

One of the Holy Grails in cell ther­a­py right now is the de­vel­op­ment of off-the-shelf cells that can be used in any pa­tient, the po­lar op­po­site of the per­son­al­ized CAR-Ts now rolling in­to the mar­ket from No­var­tis and Gilead. And one of the lead­ers in the field us­ing gene edit­ing tech­nolo­gies to cre­ate these cell ther­a­pies is ap­pro­pri­ate­ly called Uni­ver­sal Cells, based in Seat­tle.

To­day, Uni­ver­sal Cells added a new part­ner to its grow­ing list of tech part­ners. Astel­las is hand­ing over a $9 mil­lion up­front and promis­ing up to $115 mil­lion more in mile­stones so that the new part­ners can get start­ed on de­vel­op­ing a new cell ther­a­py for an un­spec­i­fied tar­get.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.